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Significance {#sec1}
============

**Leukemia stem cells play central roles in disease progression and recurrence due to their intrinsic capacity for self-renewal and chemotherapy resistance. However, few regulators of human LSC function are known. Our study establishes that miRNA plays a powerful role in governing the fundamental properties that define the stemness state of human LSC including quiescence, self-renewal, and chemotherapy response. Self-renewal regulators have remarkably parallel functions in malignant and normal stem cells, precluding their therapeutic targeting because of toxicity to normal stem cells. The opposing self-renewal outcomes governed by miR-126 within HSC and LSC indicate that despite shared stemness determinants, it may be possible to target therapeutically the networks that specifically control LSC through perturbation of miR-126 levels.**

Introduction {#sec2}
============

Acute myeloid leukemia (AML) is organized as an aberrant developmental hierarchy maintained by functionally distinct leukemia stem cells (LSC) ([@bib29]). LSC are linked to therapy failure and disease recurrence, but they also share many biological properties with hematopoietic stem cells (HSC), including capacity for self-renewal and quiescence ([@bib29]). Several self-renewal regulators have been studied in both HSC and LSC contexts including PTEN, BMI1, GFI1, TEL1, STAT5, and JUNB; except for PTEN, loss of function typically impairs self-renewal of both LSC and HSC ([@bib59]). LSC and HSC are both quiescent, although quiescence regulation is better understood in HSC. Several intrinsic and extrinsic signals converge upon cyclins and cyclin-dependent kinases (CDKs) that act upstream of Retinoblastoma (RB) family members to regulate early and late G~1~ progression in HSC ([@bib55]), while the G~0~ state is governed by MTORC1 and CDK6 ([@bib30], [@bib47]). Quiescence and distinct G~0~ exit kinetics are essential HSC properties ([@bib50]). Although LSC quiescence is less well defined, the known regulators appear to function similarly in LSC and HSC, with LSC quiescence often invoked as a mechanism of chemotherapy resistance ([@bib22]). Additional studies are required to determine if differences exist in self-renewal and quiescence regulation between LSC and HSC and whether it is possible to develop therapies that eradicate LSC while sparing HSC.

Transcriptional analysis of human HSC and functionally defined LSC have defined stemness signatures that are highly prognostic for patient survival, establishing that LSC-specific properties are clinically relevant ([@bib13], [@bib38]). However, little is known of how stemness programs are controlled. Several differentially expressed miRNAs were identified and found to control HSC ([@bib25], [@bib31], [@bib37], [@bib43]) by coordinate repression of multiple targets ([@bib12]). In hematopoiesis, most miRNAs affect progenitor lineage commitment and mature cell function ([@bib51]), although HSC self-renewal can be governed by miR-125a/b, miR-29a, and miR-126 ([@bib42], [@bib43], [@bib19], [@bib31]). miR-126 plays a role, conserved in both human and mouse, in maintaining HSC quiescence by attenuating the cellular response to extrinsic signals via targeting multiple components of the PI3K/AKT/GSK3B signaling pathway ([@bib31]). Thus, HSC expand without concomitant exhaustion upon miR-126 silencing.

Deregulation of miRNAs occurs in leukemia correlating with known risk categories and prognosis ([@bib15], [@bib32], [@bib35]). Functionally, miRNA overexpression can induce murine leukemic transformation ([@bib21], [@bib43], [@bib49]). Several LSC-associated miRNAs are functional: miR-17-92 polycistron maintained LSC in MLL models ([@bib56]), whereas antagonizing miR-196 and miR-21 reduced LSC in an experimental human MLL model ([@bib54]). Targeted miR-126 reduction in cell lines and primary AML samples reduced AML growth, although mechanisms were not reported ([@bib10], [@bib11]). These promising studies point to the importance of further understanding the role of miRNA in governing stemness in AML. Here, we investigated the role of miR-126 in governing LSC self-renewal, quiescence, and chemotherapy resistance.

Results {#sec3}
=======

LSC miRNA Signature Is Prognostic for Patient Outcome {#sec3.1}
-----------------------------------------------------

To determine whether miRNA are differentially expressed in LSC and HSC, we fractionated 16 AML patient samples and three lineage-depleted (Lin^--^) cord blood (CB) samples using CD34 and CD38 into four populations and subjected each to global miRNA profiling; the stem cell content of each fraction was functionally assayed by xenotransplantation ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}A). Bioinformatic analysis of 25 LSC-enriched and 27 fractions devoid of LSC activity ([Figure S1](#mmc1){ref-type="supplementary-material"}A) revealed a human LSC-associated miRNA signature derived from in vivo functionally validated AML patient samples ([Figure 1](#fig1){ref-type="fig"}B). In parallel, miRNAs enriched in HSC or committed progenitors were determined ([Figure S1](#mmc1){ref-type="supplementary-material"}B). By comparing similar immunophenotypic AML and normal populations, several differentially expressed miRNAs were found ([Figure S1](#mmc1){ref-type="supplementary-material"}C).

To determine if the LSC-associated miRNA signature was clinically relevant, a regression analysis was performed on 74 AML patients with normal cytogenetics (PMCC cohort, [Table S1](#mmc1){ref-type="supplementary-material"}). An optimized LSC signature consisting of four miRNAs was identified, each with differential weights based on impact upon overall survival (OS) ([Figure 1](#fig1){ref-type="fig"}C). This signature was prognostic of OS in both univariate ([Figure 1](#fig1){ref-type="fig"}D) and multivariate analyses ([Figure 1](#fig1){ref-type="fig"}E) in an independent cohort. Together with prior studies showing that LSC-specific gene expression signatures are significantly prognostic ([@bib13], [@bib17]), these data establish that LSC properties influence clinical outcomes and that miRNAs play a powerful role in regulating LSC stemness.

miR-126 Bioactivity Enriches for LSC Activity {#sec3.2}
---------------------------------------------

Further functional studies on AML focused on miR-126 as it is a known HSC regulator ([@bib31]). qPCR independently confirmed that LSC-containing AML fractions generally expressed the highest miR-126 levels ([Figure S2](#mmc1){ref-type="supplementary-material"}A). As miRNA expression does not uniformly equate with miRNA bioactivity, a miR-126 lentiviral reporter vector was used to investigate whether miR-126 is biologically active in LSC ([@bib16]); ΔNGFR levels indicate transduced cells, while EGFP levels are inversely correlated with miR-126 bioactivity ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Four primary AML samples ([Table S2](#mmc1){ref-type="supplementary-material"}) were transduced with the reporter, transplanted into xenografts, and after 12 weeks the engrafting population was sorted solely on the basis of miR-126 bioactivity ([Figure 2](#fig2){ref-type="fig"}A). Each sorted population was transplanted into secondary mice and LSC activity scored after 8 weeks, based on whether the engrafting population recapitulated the same EGFP/ΔNGFR flow profile as the primary recipient (a cardinal property of cancer stem cells). Despite the presence of LSC activity in multiple subpopulations with CD34 and CD38 sorting ([Table S2](#mmc1){ref-type="supplementary-material"}), miR-126 bioactivity aggregated all LSC activity into a single miR-126^high^ population ([Figure 2](#fig2){ref-type="fig"}B). qPCR confirmed 40-fold higher mature miR-126 levels in LSC-engrafting fractions compared with non-engrafting fractions for three AML samples ([Figure S2](#mmc1){ref-type="supplementary-material"}C). LSC-containing fractions also had the highest clonogenic ([Figure S2](#mmc1){ref-type="supplementary-material"}D) and proliferative potential ([Figure S2](#mmc1){ref-type="supplementary-material"}E). These data indicate that miR-126 bioactivity is directly linked to LSC function and that it is possible to exploit miRNA bioactivity for prospective LSC isolation, circumventing often unreliable and heterogeneously expressed cell surface markers ([@bib29]).

Clinical Relevance of miR-126 Expression {#sec3.3}
----------------------------------------

To determine if miR-126 expression alone is prognostic, the PMCC cohort ([Table S1](#mmc1){ref-type="supplementary-material"}) was investigated, and increased miR-126 expression was found to be associated with worse OS (median OS of 28.5 months \[high expression\] versus not reached \[low expression\]; [Figure 2](#fig2){ref-type="fig"}C), event-free survival ([Figure 2](#fig2){ref-type="fig"}D), and relapse-free survival ([Figure 2](#fig2){ref-type="fig"}E), a result in keeping with other studies ([@bib10], [@bib11]). Since miR-126 expression is high in patients with t(8; 21) and inv(16) ([@bib32]), we evaluated the prognostic value of miR-126 after excluding these patients from The Cancer Genome Atlas (TCGA) dataset. High miR-126 was associated with decreased survival in the TCGA dataset (median OS of 12.3 months \[high expression\] versus 18.5 months \[low expression\]; [Figure 2](#fig2){ref-type="fig"}F). The prognostic significance of miR-126 further strengthens the link between AML patient outcomes, stemness properties, and the regulatory of role of miRNA ([@bib17]).

Development of a Functionally Relevant Human AML Model for Mechanistic Studies {#sec3.4}
------------------------------------------------------------------------------

How miR-126 functions throughout the AML hierarchy is difficult to investigate since functional studies in primary AML cells are technically challenging and hitherto no human AML cell lines recapitulate the hierarchical organization of primary cells. Therefore, we developed an indefinitely growing AML culture system (8227) from a relapse sample that is organized as a functional hierarchy ([Figure 3](#fig3){ref-type="fig"}A) (E.L., unpublished data). Expression of CD34 and CD38 is tightly linked to the functional hierarchy; CD34^+^CD38^−^ cells possess LSC activity and contain a quiescent population, by contrast CD34^+^CD38^+^ cells are enriched in clonogenic progenitors and the remaining 90% of CD34^−^CD38^+^ and CD34^−^CD38^−^ cells are terminally differentiated CD15^+^CD14^+^ blasts ([Figure 3](#fig3){ref-type="fig"}A). We show through an integrated analysis of function, phenotype, miR-126 bioactivity, and promoter methylation status on all sorted fractions that high miR-126 levels correlate with the CD34^+^CD38^−^ phenotype and LSC activity and are linked to EGFL7 expression and stem cell-specific promoter methylation patterns ([Figure S3](#mmc1){ref-type="supplementary-material"}A and E.L., unpublished data). Thus, 8227 cells are a relevant model culture system for interrogating the functional effects of miR-126 activity within the context of a leukemic hierarchy.

miR-126 Expression Induces Quiescence in Primitive AML Cells {#sec3.5}
------------------------------------------------------------

To investigate the functional importance of miR-126 within the AML developmental hierarchy, 8227 cells were transduced with an mOrange (mO) lentivirus expressing miR-126 (126OE) or empty control vector (CTRL) ([Figure S3](#mmc1){ref-type="supplementary-material"}B), and elevated miR-126 levels were confirmed ([Figure 3](#fig3){ref-type="fig"}B). Following in vitro propagation of transduced cells, the mO^+^CD34^+^CD38^--^ (surrogate LSC) population was sorted and the proliferative, differentiation, and clonogenic capacity was evaluated over 28 days. By 7 days, primitive CD34^+^ cells increased ([Figure 3](#fig3){ref-type="fig"}C) and differentiated CD14^+^CD15^+^ cells decreased ([Figure S3](#mmc1){ref-type="supplementary-material"}C) in the 126OE group. This proportional increase in CD34^+^ cells correlated to transient reductions in clonogenicity of day 0 bulk cultures ([Figure S3](#mmc1){ref-type="supplementary-material"}D); a reduction primarily confined to CD34^+^CD38^+^ clonogenic fractions ([Figure 3](#fig3){ref-type="fig"}D). Bulk cultures of the 126OE group had significantly decreased (15%) bromodeoxyuridine (BrdU) incorporation at 3 hr (p = 0.002) and 16 hr (p = 0.001) compared with CTRL ([Figure 3](#fig3){ref-type="fig"}E). No differences in apoptosis were observed (data not shown). Cell cycle analysis of sorted 126OE populations at 7 days showed 2-fold increased proportions of quiescent (G~0~) CD34^+^CD38^−^ cells and decreased S/G~2~/M cells ([Figures 3](#fig3){ref-type="fig"}F and [S3](#mmc1){ref-type="supplementary-material"}E). By contrast, the G~0~ status of 126OE CD34^+^CD38^+^ and CD34^−^ populations remained unaffected (data not shown). Thus, 126OE maintains 8227 cells in a more primitive state by increasing the proportion of quiescent CD34^+^CD38^--^ cells, thereby decreasing the overall proliferative output and differentiation of AML blasts.

miR-126 Knockdown Provokes LSC Entry into Cycle {#sec3.6}
-----------------------------------------------

To determine the impact of miR-126 knockdown, 8227 cells were transduced with lentiviruses that were empty (CTRL) or expressing an miR-126 sponge (126KD) ([Figure S3](#mmc1){ref-type="supplementary-material"}F) ([@bib31]). Following sorting and culture, 126KD of the EGFP^+^CD34^+^CD38^--^ population resulted in increased output of CD34^+^ cells at all time points ([Figure 3](#fig3){ref-type="fig"}G), without increasing differentiation ([Figure S3](#mmc1){ref-type="supplementary-material"}G). This effect was primarily localized to the CD34^+^CD38^--^ compartment ([Figure 3](#fig3){ref-type="fig"}H). Clonogenic potential within the CD34^+^CD38^−^ LSC-enriched compartment increased while no differences were observed in the CD34^+^CD38^+^ progenitor-enriched compartment ([Figure 3](#fig3){ref-type="fig"}I). 126KD increased BrdU incorporation by 20% at 3 hr (p = 0.0024) and 16 hr (p = 0.0093) ([Figure 3](#fig3){ref-type="fig"}J) without affecting apoptosis (data not shown). Upon 126KD, the proportion of cells in G~0~ was decreased (30%) and S/G~2~/M increased (3-fold) within EGFP^+^CD34^+^CD38^−^ populations ([Figures 3](#fig3){ref-type="fig"}K and [S3](#mmc1){ref-type="supplementary-material"}H). 126KD of CD34^+^CD38^+^ cells trended in the same direction (CTRL G~0~ 16.07% versus 126KD G~0~ 11.54%, p = 0.2); CD34^−^ and non-transduced populations were unaffected (data not shown). Within bulk 126KD cultures, the increased cell cycle and clonogenicity ([Figure S3](#mmc1){ref-type="supplementary-material"}I) was primarily due to effects on CD34^+^CD38^--^ cells ([Figure 3](#fig3){ref-type="fig"}H). As LSC-enriched CD34^+^CD38^--^ cells are less clonogenic than CD34^+^CD38^+^ cells, we interpret these data as 126KD driving CD34^+^CD38^--^ cells out of their quiescent stem-like state and into a more committed population of proliferating clonogenic cells while retaining a primitive cell surface phenotype.

Enforced Expression of miR-126 Expands LSC In Vivo {#sec3.7}
--------------------------------------------------

To test the prediction that miR-126 maintains a primitive state by restraining entry into the cell cycle of LSC from patients, nine AML samples were transduced with 126OE and CTRL vectors and transplanted into NSG mice ([Tables S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}). Transduction efficiency and expression varied ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B), while leukemic engraftment was similar between CTRL and 126OE groups ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Although the initial transduction efficiency was ∼50% lower for 126OE than CTRL in six of nine AML samples, mOrange^+^ cells within the human CD45^+^ graft was higher for six of nine AML samples indicating a competitive advantage for 126OE groups ([Figure S4](#mmc1){ref-type="supplementary-material"}D). Analysis of primitive cell engraftment used both CD34 and CD117, as CD117 is associated with AML clinical outcome and correlated with miR-126 expression ([@bib11], [@bib48]). Phenotypic primitive cells were increased in 126OE groups for seven of nine samples ([Figure 4](#fig4){ref-type="fig"}A) with concomitant reduction of differentiated cells; four of nine samples showed a significant reduction for CD15^+^ cells ([Figure 4](#fig4){ref-type="fig"}B), and six of nine showed a trend for reduced CD14^+^ blasts ([Figure S4](#mmc1){ref-type="supplementary-material"}E). 126OE caused an increase in CD15^+^ blasts for two samples ([Figure 4](#fig4){ref-type="fig"}B).

To evaluate 126OE on LSC function within the xenografts, serial transplantation with limiting dilution analysis was used to quantify LSC numbers. In three samples, LSC frequency increased in the 126OE group ([Figures 4](#fig4){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}F). Although individual patient samples exhibited variation, overall, 126OE increased LSC self-renewal and reduced differentiation leading to LSC expansion.

miR-126 Knockdown Targets LSC In Vivo {#sec3.8}
-------------------------------------

126KD was used to determine whether reducing miR-126 would impair AML engraftment or LSC function ([Figure S5](#mmc1){ref-type="supplementary-material"}A). Total levels of human CD45^+^ ([Figure S5](#mmc1){ref-type="supplementary-material"}B) or CD45^+^EGFP^+^ engraftment ([Figure S5](#mmc1){ref-type="supplementary-material"}C) were unaffected in the 126KD group, although there was heterogeneity. By contrast, primitive CD117^+^ blasts were reduced in three of seven in the 126KD group, while two of seven had increased CD117^+^ blasts ([Figure 5](#fig5){ref-type="fig"}A); differentiated CD15^+^CD14^+^ cells were increased in four of seven samples ([Figure 5](#fig5){ref-type="fig"}B). The LSC frequency was reduced in two of three samples upon 126KD ([Figures 5](#fig5){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}D). Together, these findings suggest that 126KD produces heterogeneous responses with LSC function and frequency reduced in a subset of AML patients.

PI3K/AKT/MTOR Is Targeted by miR-126 in Primitive AML Cells {#sec3.9}
-----------------------------------------------------------

An integrated transcriptional and proteomic approach was employed to gain mechanistic insight into miR-126 functioning. Quantitative protein mass spectrometry (MS) was performed on bulk 126OE and CTRL 8227 cells resulting in the identification and quantification of 8,848 and 4,837 proteins, respectively. In parallel, gene expression profiling was undertaken on 126KD, 126OE or CTRL CD34^+^CD38^--^, and CD34^+^CD38^+^ 8227 cells. Gene set enrichment analysis (GSEA) of the proteomics dataset identified pathways and leading edge genes directly targeted by miR-126. In post-analysis, transcriptomic datasets were correlated with proteomic-modulated pathways ([Figure 6](#fig6){ref-type="fig"}A). The most significant pathways identified centered on PI3K/AKT/MTOR signaling, a miR-126 target pathway previously validated in primitive normal human CB cells ([@bib31]). In addition, the protein MS data revealed a strong quiescence signature ([Figure S6](#mmc1){ref-type="supplementary-material"}A) substantiating the in vitro cell cycle effects ([Figures 3](#fig3){ref-type="fig"} and [S3](#mmc1){ref-type="supplementary-material"}). Additional BrdU labeling studies with miR-126OE and miR-126KD confirmed these cell cycle effects in vivo ([Figures S6](#mmc1){ref-type="supplementary-material"}B and S6C). The proteomic analysis was validated and confirmed by western blot of 8227 cells showing that ADAM9, PIK3R2 (p85beta), and AKT levels are reduced in 126OE groups ([Figure 6](#fig6){ref-type="fig"}B). Although AKT is not a predicted miR-126 target, the protein MS data show that all three AKT isoforms are reduced by 126OE ([Table S4](#mmc2){ref-type="supplementary-material"}). In addition, many predicted and validated miR-126 targets are signaling inputs for AKT activity ([@bib36]). To activate AKT, PDK1 is required to phosphorylate AKT on Thr^308^ in the activation loop. We found that pPDK1 Ser^241^ is reduced with 126OE, suggesting PDK1 activity is reduced by miR-126, further dampening AKT activation ([Figure 6](#fig6){ref-type="fig"}C). MTORC2 plays a critical role in AKT Ser^473^ phosphorylation, a prerequisite for full AKT activation. Our proteomics analysis found that MAPKAP1 (Sin1) was downregulated by 126OE ([Figure 6](#fig6){ref-type="fig"}A) and since MAPKAP1 is required for MTORC2 complex formation ([@bib57]), its reduction is predicted to reduce MTORC2 activity. Finally, since PTEN antagonizes the PI3K/AKT signaling pathway by dephosphorylating phosphoinositides, and no change in total PTEN levels were observed by protein MS, we checked pPTEN Ser^380^ status and found increased pPTEN Ser^380^ phosphorylation; a modification thought to stabilize PTEN and maintain its function ([@bib1]). Collectively, this integrated analysis provides strong data that miR-126 expression dampens many components of the PI3K/AKT/MTOR signaling pathway in primitive AML populations.

To characterize miR-126 targets not identified by proteomics or GSEA, all genes upregulated with 126KD and downregulated with 126OE ([Figure S6](#mmc1){ref-type="supplementary-material"}D) were compared in collated lists of predicted miR-126 targets generated from four published prediction algorithms. Genes were ranked according to the level of perturbation by miR-126 ([Figure S6](#mmc1){ref-type="supplementary-material"}E). Selected candidates including ADAM9, ILK, GOLPH3, CDK3, and TOM1 were confirmed as miR-126 targets using 3′ UTR luciferase reporter assays ([Figure S6](#mmc1){ref-type="supplementary-material"}F) ([@bib20], [@bib41]).

PI3K/AKT signaling ultimately converges upon cyclins and CDK that promote RB1 phosphorylation and cell cycle entry. The uncovering of CDK3 as a potential miR-126 target was intriguing as miR-126 reduces cell cycle progression and CDK3 was previously identified as a gatekeeper of G~0~-G~1~ cell cycle control ([@bib46]). The PI3K/AKT/MTOR pathway regulates CDKN1B (p27^kip^) protein stability by controlling the levels of SKP2, a component of the SCF^SKP2^ ubiquitin ligase complex ([@bib33]). Both chemical inhibition of PI3K or enforced expression of PTEN induces p27^kip^ upregulation in quiescent cells ([@bib8], [@bib34]) and CDK3 activity is downregulated with transient p27^kip^ expression ([@bib5], [@bib24]). To test the hypothesis that miR-126 modulation of PI3K/AKT/MTOR signaling influences LSC function through CDK3, functional studies were undertaken. Intracellular flow cytometry of 8227 cells showed reduced CDK3 protein levels and pRB Ser^807/811^ levels upon 126OE ([Figure 6](#fig6){ref-type="fig"}D). CDK3/cyclin C phosphorylation of RB1 on Ser^807/811^ is required to induce cell cycle entry from a quiescent state (G~0~ exit) ([@bib46]) ([@bib39]) To verify that 126OE functions are dependent on CDK3 downregulation, lentiviruses expressing CDK3 or the CDK3 kinase mutant (CDK3mut) were generated ([Figure S6](#mmc1){ref-type="supplementary-material"}G) ([@bib53]). Compared with CDK3mut, CDK3 significantly increased proliferation and clonogenicity of CD34^+^CD38^--^ and CD34^+^CD38^+^ cells ([Figures 6](#fig6){ref-type="fig"}E and 6F), and partially reversed 126OE-induced expansion of CD34^+^ cells ([Figures 6](#fig6){ref-type="fig"}G and [S6](#mmc1){ref-type="supplementary-material"}H). Collectively, these data suggest that miR-126 restricts LSC proliferation partly through targeting CDK3.

High miR-126 Bioactivity Endows LSC with Chemotherapy Resistance {#sec3.10}
----------------------------------------------------------------

To test whether the induction of LSC quiescence by 126OE is associated with chemotherapy resistance, 126OE or CTRL transduced 8227 cells were exposed to increasing concentrations of daunorubicin. 126OE increased the survival of CD34^+^ cells after 72 hr of treatment compared with CTRL ([Figure 7](#fig7){ref-type="fig"}A), an effect not seen in non-transduced cells ([Figure S7](#mmc1){ref-type="supplementary-material"}A). Treatment of primary AML samples ([Table S5](#mmc1){ref-type="supplementary-material"}) with daunorubicin plus cytarabine resulted in enrichment of primitive CD117^+^ cells ([Figure S7](#mmc1){ref-type="supplementary-material"}B) and increased miR-126 levels in four of five samples ([Figure 7](#fig7){ref-type="fig"}B). Thus, primitive AML cells expressing the highest miR-126 levels are also the most resistant to anti-proliferative chemotherapy.

To determine if miR-126 expression could be linked to chemotherapy resistance in a clinical setting, biobanked samples were identified from eight AML patients who failed to achieve complete remission after induction therapy. CD45^dim^ blasts were isolated from bone marrow at diagnosis (n = 8, day 0), day 14 (n = 4), and day 30 (n = 5) post-induction, and at day 30 after salvage chemotherapy (n = 3). In line with the in vitro findings, miR-126 expression was increased in six of eight samples (median, 3.4-fold; range, 0.3--9.4) after induction, and in two of three patients (including one in whom miR-126 expression was unchanged after induction) following salvage chemotherapy (median, 1.8-fold; range, 1.1--2.1) ([Figures 7](#fig7){ref-type="fig"}C and [S7](#mmc1){ref-type="supplementary-material"}C). miR-126 expression was higher in relapse blasts compared with paired diagnostic samples in all four patients tested ([Figures 7](#fig7){ref-type="fig"}D and [S7](#mmc1){ref-type="supplementary-material"}D). miR-126 expression in primitive CD45^dim^CD117^+^ cells was increased in eight of ten patients at relapse, with \>100-fold enrichment in two patients ([Figures 7](#fig7){ref-type="fig"}E and [S7](#mmc1){ref-type="supplementary-material"}E). Finally, enforced expression of CDK3 in 8227 cells rescued the 126OE effects by decreasing the proportion of CD34^+^ cells resistant to daunorubicin and cytarabine ([Figure 7](#fig7){ref-type="fig"}F). Overall, these data suggest that miR-126 confers resistance to chemotherapy, likely through the induction and maintenance of cellular quiescence by the targeting and repression of the PI3K/AKT/MTOR pathway.

Discussion {#sec4}
==========

Our study establishes that miRNAs play a powerful role in governing the fundamental properties that define the stemness state of human LSC including quiescence, self-renewal, and chemotherapy response. miRNAs are differentially expressed within distinct cellular subsets that make up the AML hierarchy, with a restricted set expressed in an LSC-specific manner. The miRNA LSC signature was itself highly prognostic. This clinical association, together with the miR-126 functional data, establishes that miRNAs provide a layer of post-transcriptional control critical for maintaining the stemness state in AML. Although miR-126 governs the stemness and quiescence properties of both HSC and LSC, miR-126 perturbation results in divergent self-renewal outcomes. This discordance provides a novel avenue to therapeutically target LSC without attendant toxicity to HSC.

Our study provides a mechanistic link between quiescence control and the restraint of CDK3 expression by miR-126, thereby altering RB1 phosphorylation and delaying G~0~ exit in human primitive AML populations. Regulation of G~0~ exit kinetics is a fundamental HSC property, distinct from downstream progenitors, that is essential for maintaining HSC pool integrity ([@bib30], [@bib40]). CDK3 is poorly studied since all inbred mice carry a nonsense mutation in CDK3 ([@bib58]). In quiescent human fibroblasts, CDK3 can complex with CCNC (cyclin C) and phosphorylate Rb1 (on residues S^807^ and S^811^) to directly initiate the cell cycle; when CDK3 levels are reduced, a 12-hr lag in G~0~ exit kinetics is induced but not a permanent block ([@bib46]). In murine LT-HSC, CCNC levels are highest during G~0~ exit ([@bib44]) and CCNC knockdown in human HSC increased quiescence, promoted HSPC expansion, and increased repopulation capacity ([@bib39]). In leukemia, CCNC deletion highly correlates with relapse ([@bib52]). Thus, it is likely that the miR-126/CDK3 regulatory axis also governs G~0~ exit kinetics in LSC, thereby providing new therapeutic opportunities for targeting quiescence control of LSC.

A model derived from our proteomic and transcriptomic data ([Figure 8](#fig8){ref-type="fig"}) depicts that upstream of CDK3, miR-126 represses multiple inputs converging on PI3K/AKT/MTOR signaling in LSC, paralleling miR-126 function in HSC ([@bib31]). Preclinical evidence indicates that activated PI3K/AKT/MTOR signaling plays a role in AML ([@bib36]) despite being rarely mutated and likely driven by upstream activation ([@bib14]). Although inhibitors of AKT, MTOR, and PI3K are in clinical development, they have mostly failed for AML ([@bib14]). While failure is attributed to feedback loops, our study provides an explanation that is embedded in the hierarchical organization of AML. PI3K/AKT/MTOR signaling is restricted to cycling leukemic progenitors; by contrast, quiescent LSC, a reservoir of leukemic relapse, have lower signaling and would then be spared following inhibitor treatment. In support of this prediction, AKT inhibition increased the fraction of G~0~ breast cancer cells, linking low AKT signaling to a G~0~-like state ([@bib9]). In AKT knockout mice, HSC persisted in an enhanced G~0~ quiescent state, while AKT activation results in HSC hyper-proliferation and exhaustion ([@bib27], [@bib28]). Collectively, these reports suggest that the state of AKT activity plays a key role in governing quiescence of normal HSC and our data extend this concept to leukemia by showing that this pathway is tightly controlled at multiple points by miRNAs in order to maintain the human LSC state.

Although cell cycle regulation by miR-126 is similar between HSC and LSC, the functional consequence is the opposite: reduced miR-126 levels expand HSC in vivo, but impair LSC maintenance (see the model in [Figure 8](#fig8){ref-type="fig"}). With the exception of PTEN, known regulators of self-renewal have similar functions in normal and leukemic contexts ([@bib59]). PTEN is rarely mutated in AML, yet experimental deletion results in HSC loss and LSC expansion, supporting our data on functional HSC--LSC divergence. Concordant with our findings of low PI3K/AKT/MTOR signaling in dormant LSC, rapamycin treatment only eliminates LSC during the early phases of leukemic initiation in PTEN mouse models when LSC are proliferating, but not when leukemia is fully developed and when some LSC are predicted to re-enter quiescence ([@bib59]).

While targeting stemness represents a promising clinical direction, finding a selective therapeutic window might be challenging due to the shared determinants of stemness between HSC and LSC, and the likelihood of causing excessive toxicity ([@bib29]). The distinct function of miR-126 in HSC and LSC provides an opportunity to clinically target LSC while sparing HSC. Moreover, inhibiting miR-126 might overcome LSC chemo-resistance through cycle activation and increasing sensitivity to anti-proliferative drugs. Although targeting miRNA in vivo is still inefficient ([@bib6]), LNA miRNA decoy technology is effective clinically in hepatitis C ([@bib26]). Alternatively, targeting the LSC-specific pathways identified by miR-126 might also be an effective strategy.

Experimental Procedures {#sec5}
=======================

Patient-Derived Xenografts {#sec5.1}
--------------------------

NOD/Lt-scid/IL2Rɣnull (NSG) mice were bred at the University Health Network/Princess Margaret Cancer Center. Animal experiments were performed in accordance with national and institutional guidelines approved by the Canadian Counsel on Animal Care and approved by the University Health Network Animal Care Committee. Mouse xenografts were performed as described previously ([@bib31]). Briefly, NSG mice were sublethally irradiated (225 cGy) 1 day prior to injection. AML patient samples were thawed and plated in X-VIVO/20% BIT (Stem Cell Technologies) supplemented with Flt3-L (50 ng/ml), IL-6 (10 ng/ml), stem cell factor (50 ng/ml), thrombopoietin (125 ng/ml), IL-3 (10 ng/ml), granulocyte colony-stimulating factor (10 ng/ml) for 18 hr ([@bib2]). Cells were transduced in 24-well culture plates at a multiplicity of infection of 30 with sensor lentivectors or for enforced expression and knockdown of miR-126. Transduced AML cells (5 × 10^5^--1 × 10^6^) were injected with 25 μl of PBS into the right femur of each recipient mouse. After 10--12 weeks, the mice were euthanized and bone marrow cells were flushed with 2 ml of PBS, 2% fetal calf serum, and 50 μl of cells were stained for surface markers.

Patient Samples and Treatment Protocols {#sec5.2}
---------------------------------------

Between 2003 and 2010, peripheral blood and bone marrow samples were collected from subjects with AML after obtaining informed consent according to procedures approved by the Research Ethics Board of the University Health Network (REB\# 01-0573-C). Mononuclear cells were isolated and stored as previously described ([@bib13]). Cytogenetics were analyzed according to the revised MRC prognostic classification system ([@bib18]). *NPM1* and *FLT3*-ITD mutations were assessed as previously described ([@bib23]).

The 74 patient samples used to optimize the miRNA prognostic signature (PMCC cohort) were diagnostic samples from individuals with de novo AML and normal cytogenetics. Although patients were not treated uniformly, all initially received induction chemotherapy followed by two cycles of consolidation in those who achieved complete remission (CR). First-line induction regimens included 3 + 7 (n = 69), NOVE-HIDAC (n = 1), and four patients were enrolled in clinical trials employing a 3 + 7 backbone with gemtuzumab ozogamicin (n = 2) or tipifarnib (n = 2). Treatment protocols were as previously described ([@bib3], [@bib4], [@bib23], [@bib45]). Allogeneic stem cell transplant (allo-SCT) was performed for high-risk patients in CR1 (n = 7), as well as for patients who achieved a second remission after relapse (n = 12) if they had an available donor, were younger than 70 years, lacked significant comorbidities, and had good performance status. Bio-informatic and clinical information for a second cohort of 187 de novo AML patients was obtained from TCGA and has been previously described ([@bib7]).

See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for additional methods.
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![Generation and Validation of an LSC-Enriched miRNA Signature\
(A) Schematic depicting the strategy to fractionate human AML patient samples based on immuno-phenotypic staining for CD34 and CD38. Functional validation of sorted fractions was performed by xenotransplantation, the result of which was combined with miRNA expression profiling to generate stem cell-related miRNA expression profiles.\
(B) Heatmap and summary of miRNAs enriched within the LSC and non-LSC populations.\
(C) The optimized miRNA signature derived from regression analysis of the PMCC cohort and the weight each miRNA adds to the overall signature.\
(D and E) Validation of the optimized LSC-associated miRNA signature shown in (C) in the TCGA cohort (n = 187) by (D) univariate analysis (hazard ratio \[HR\], 2.04; p \< 0.0001) and (E) multivariate analysis (HR, 2.53; p = 0.003). See also [Figure S1](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![miR-126 Bioactivity Marks the Functional LSC Compartment in Human AML\
(A) Schematic describing the sorting scheme/scoring system for secondary mice. AML samples were transduced with an miR-126 reporter construct and transplanted into conditioned NSG mice for 12 weeks. Bone marrow was analyzed for engraftment using CD45^+^ΔNGFR^+^EGFP^+^ staining. Cells were sorted into four populations based on ΔNGFR (transduced cells) and EGFP expression (inverse of miR-126 bioactivity), counted, and injected into secondary mice for 8--10 weeks. When a ΔNGFR/EGFP profile is recapitulated in secondary mice, the mouse is scored as engrafted.\
(B) Summary of the results of the miR-126 bio-reporter assays.\
(C) Kaplan-Meier overall survival (OS) curves in the PMCC CN AML cohort (n = 74) according to the miR-126 expression level (HR, 2.23; p = 0.00901).\
(D) Univariate Cox model analysis for miR-126 as prognostic for event-free survival in the PMCC cohort of CN AML patients (n = 74; p = 0.0207, log rank test, median split; HR, 1.8744; p = 0.0207, Wald test).\
(E) Kaplan-Meier survival curves correlating miR-126 expression and relapse-free survival in the PMCC patient cohort. Univariate median split log rank test (HR, 1.7995; p = 0.033, Wald test).\
(F) Univariate analysis for OS in the TGCA AML cohort that encompasses all levels of cytogenetic risk (n = 187) according to the miR-126 expression level (HR, 1.41; p = 0.0382). See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Enforced Expression and Knockdown of miR-126 Alters the Proliferation and Differentiation Status of Primitive 8227 AML Cells\
(A) Illustration showing flow plots of CD34 and CD38 immunostained 8227 cultures. The red gated (CD34^+^CD38^-^) population is enriched in quiescent LSC and reinitiates the original hierarchy in vitro after flow sorting. The blue gated population (CD34^+^CD38^+^) is enriched in colony-forming unit (CFU) potential and represents the AML progenitor compartment. Both green and orange gated CD34^−^ compartments are devoid of LSC and CFU activity, express CD15 and CD14 differentiation markers, and represent terminally differentiated mature AML blasts.\
(B) Relative expression of mature miR-126-3p in 8227 cells 7 days after transduction with lentivectors expressing miR-126 (126OE) or an empty control vector (CTRL) measured by qPCR.\
(C) The proportion of CD34^+^ cells over the time course of culture of 126OE and CTRL cells.\
(D) Clonogenic potential of sorted subpopulations of 8227 cells after transduction with CTRL or 126OE vectors plated immediately post-sort.\
(E) Percent BrdU incorporation into bulk cultures showing proliferation of CTRL and 126OE transduced 8227 cells over time.\
(F) Ki67/Hoechst cell cycle staining of CD34^+^CD38^−^ LSC-enriched 8227 cells.\
(G and H) Percentage of total CD34^+^ (G) and primitive CD34^+^CD38^--^ and CD34^+^CD38^+^ progenitor cells (H) at day 8 and day 15 post-sort in vitro in 8227 culture after sponge-mediated miR-126 knockdown.\
(I) Day 0 post-sort colony-forming potential of sorted fractions of CTRL and 126KD 8227 cells.\
(J) Proliferation measured by BrdU incorporation assay of CTRL or 126KD transduced 8227 cells in vitro.\
(K) Cell cycle analysis of CD34^+^CD38^−^ 8227 cells measured by Ki67/Hoechst staining.\
Data are shown as means ± SEM of three biological replicate experiments. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![Enforced Expression of miR-126 Expands Primary AML LSC\
(A) Representative flow plots depicting changes in CD117^+^ and CD34^+^ levels upon 126OE and quantification of the percentage of CD117^+^ cells within the human CD45^+^mO+^+^ graft.\
(B) Representative flow plots depicting changes in the percentage of CD34^+^ and CD15^+^ cells within the human CD45^+^mO^+^ graft and quantification of changes in the percentage of AML cells expressing differentiation marker CD15. Data in (A) and (B) represent means ± SEM of 4--6 mice; ^∗^p \< 0.05, ^∗∗^p \< 0.01.\
(C) CD45^+^mO^+^ AML cells were flow sorted from primary mice and transplanted in limiting doses into secondary recipients for 8--10 weeks. Human CD45^+^ marking of \> 0.5% was considered positive for AML engraftment. Human grafts were confirmed to be CD33^+^CD19^−^ AML. Limiting dilution analysis was performed using ELDA software. See also [Figure S4](#mmc1){ref-type="supplementary-material"} and [Table S2](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![Diminished miR-126 Levels Reduce the Proportion of Primitive AML Cells\
(A) Representative flow plots depicting changes in CD117^+^ and CD34^+^ levels upon 126KD and quantification of the percentage of CD117^+^ cells within the human CD45^+^EGFP^+^ graft.\
(B) Representative flow plots depicting changes in the percentage of CD14^+^CD15^+^ cells within the human CD45^+^EGFP^+^ graft and quantification of changes in percentage of AML cells expressing differentiation markers CD14 and CD15. Data in (A) and (B) represent means ± SEM of 4--6 mice; ^∗^p \< 0.05, ^∗∗^p \< 0.01.\
(C) CD45^+^EGFP^+^ AML cells were flow sorted from primary mice and transplanted at limiting doses into secondary recipients for 8--10 weeks. Human CD45^+^ marking of \>0.5% was considered positive for AML engraftment. Human grafts were confirmed to be CD33^+^CD19^--^ AML. Limiting dilution analysis was performed using ELDA software. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.](gr5){#fig5}

![PI3K/AKT/MTOR Is Targeted by miR-126 in Primitive AML Cells\
(A) Functional enrichment map for protein MS-based expression revealing miR-126 modulated pathways. Blue nodes (circles) represent gene sets enriched in proteins downregulated in 8227 cells overexpressing miR-126. Green line (edge) width between nodes corresponds to the number of shared proteins. Predicted miR-126 targets (purple triangle) are connected to enriched pathways by gray edges and edge width is proportional to the overlap significance (Wilcoxon proteomics p \< 0.05 and hypergeometric test p \< 0.05). Downregulated genes from the transcriptomics data (red diamond) are connected to enriched pathways by orange edges (Wilcoxon proteomics p \< 0.05, Wilcoxon transcriptomic p \< 0.25, and hypergeometric p \< 0.05). Thickest orange and gray edges have significant Wilcoxon and Fisher\'s exact test p \< 0.05. Map includes only nodes (cyan border) that have significant overlap with miR-126 predicted targets and expression data and connected nodes belonging to same clusters (MCL cluster algorithm called from ClusterMaker2). Gene names in gray beside each cluster are the genes that are found in the specified cluster and overlap with predicted miR-126 targets repressed in 126OE.\
(B) Western blot of ADAM9, PIK3R2, and AKT levels in 8227 cells transduced with miR-126OE or control lentivirus. GAPDH is the loading control.\
(C) Western blot of phospho-PDK1 Ser^241^ and phospho-PTEN Ser^280^ levels in 8227 cells transduced with miR-126OE or control lentivirus. GAPDH is the loading control.\
(D) Representative intracellular flow plots for the detection of CDK3 and pRB Ser^807/811^. Graph below represents three independent intracellular flow experiments for each condition where the mean fluorescence intensity was compared. Mean ± SEM; ^∗^p=\<0.05 and ^∗∗∗∗^p=\<0.0001.\
(E) Graph depicting enhanced expansion of bulk 8227 cultures after enforced expression of CDK3 and mutCDK3. Fold expansion is normalized to mutCDK3 control culture day 7 after transduction. Data shown are the mean ± SEM of three replicate experiments; ^∗^p=\<0.05.\
(F) Graph showing clonogenic potential of primitive AML cells after enforced expression of CDK3 and mutCDK3. Colony counts are shown as the mean ± SEM of three replicate experiments.\
(G) Graph depicting CDK3/OE rescue of CD34^+^ cell expansion upon 126OE. 8227 cells were transduced with miR-126, and CD34^+^CD38^--^ cells were sorted and placed into culture. Cells were transduced with viral vectors expressing the mutCDK3 control vector or CDK3 vector. Flow cytometry was performed at day 3 and day 7. The percentage of CD34^+^ cells in double-transduced cultures is shown as the mean ± SEM of three replicate experiments, where ^∗∗^p \< 0.01. See also [Figure S6](#mmc1){ref-type="supplementary-material"} and [Table S3](#mmc1){ref-type="supplementary-material"}.](gr6){#fig6}

![High miR-126 Bioactivity Endows LSC with Chemotherapy Resistance\
(A) Graphical representation of percent viable CD34^+^ 8227 cells with increasing doses of daunorubicin. CD34^+^ cell numbers were normalized to day 0 control transduced cells. Results are shown as the mean ± SEM of three biological replicate experiments; ^∗∗∗∗^p \< 0.0001.\
(B) Primary patient AML cells were plated onto MS5 stroma; after 24 hr cells were treated with vehicle or with daunorubicin (50 ng/ml)/AraC (500 ng/ml) for 72 hr. The miR-126 expression levels in daunorubicin/AraC-treated and control AML blasts were determined by qPCR. Results were normalized to RNU48 and are shown as the mean ± SD of four replicates; ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001.\
(C) qPCR was performed on CD45^dim^ sorted blasts from patient samples at diagnosis (n = 8, day 0) and at day 14 (n = 4) and day 30 (n = 5) after initiation of induction chemotherapy, as well as on day 30 after (unsuccessful) salvage chemotherapy (n = 3). Data shown are pooled from individual patients (see [Figure S7](#mmc1){ref-type="supplementary-material"}C) and are shown as means ± SEM of combined individual patient samples. ^∗^p \< 0.05.\
(D and E) qPCR results of the relative levels of miR-126 in CD45^dim^ (D, four AML patients, see [Figure S7](#mmc1){ref-type="supplementary-material"}D) and CD45^dim^CD117^+^ (E, ten AML patients, see [Figure S7](#mmc1){ref-type="supplementary-material"}E). AML blasts in paired diagnosis and relapse patient samples shown as the mean ± SEM of all patients combined; ^∗^p \< 0.05.\
(F) 8227 cells transduced with mutCDK3 and CDK3 lentiviruses were plated into a 96-well plate and treated with increasing doses of daunorubicin for 48 hr. Cells were stained for CD34 and live cells were identified by viability dye exclusion by flow cytometry. Results are shown as the mean ± SEM of four biological replicates; ^∗^p \< 0.05 and ^∗∗^p \< 0.01. See also [Figure S7](#mmc1){ref-type="supplementary-material"} and [Table S4](#mmc2){ref-type="supplementary-material"}.](gr7){#fig7}

![miR-126 Represses Multiple AKT Inputs in LSC\
LSC express high endogenous levels of miR-126 compared with more differentiated AML populations. High levels of endogenous or experimental miR-126 repress the level of several proteins regulating AKT (PI3K signaling, PI3CD, PIK3R2; integrin signaling, ADAM9, ITGA6, ILK, PARVB; RTK signaling, CRK, ABI1, CD97, CD84; MTOR signaling, MAPKAP1), reducing overall AKT levels and activity. Furthermore, high levels of miR-126 reduce pPDK1 Ser^241^, which phosphorylates AKT, and MAPKAP1, which is required for MTORC2 formation and full activation of AKT. Significantly diminished levels of AKT activity preferentially retain LSC in a quiescent state by increasing p27 levels, together with miR-126 targeted reduction of CDK3. Under high miR-126 levels, LSC that do enter the cycle are biased toward a self-renewal division. Reduction of LSC miR-126 levels through currently unspecified developmental cues (or lentiviral sponge-mediated) de-represses the expression and activity of multiple AKT signaling inputs. LSC now preferentially cycle and are biased toward differentiation divisions.](gr8){#fig8}
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